I see no reason why the FDA’s more flexible approach will not apply to RVX.  Although the document is a draft, it must reflect a view that is already circulating within the FDA. And it’s a philosophy on how trial data should be assessed, nothing to do with the conduct of future trials. It would not make sense to treat BETonMACE differently from a trial that has yet to start. 

It’s definitely very good bews imo.